exciting new anti-her2 immunotherapy(fully-humanized,no Chinese hamster ovary needed!

[Lani]

Tiptoe can relax!

Br J Cancer. 2011 May 10. [Epub ahead of print]
A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours.
Borriello M, Laccetti P, Terrazzano G, D'Alessio G, De Lorenzo C.
Source
Dipartimento di Biologia Strutturale e Funzionale, UniversitÃ* Federico II, via Cinthia, Napoli 80126, Italy.
Abstract
Background:ErbB2 is an attractive target for immunotherapy, as it is a tyrosine kinase receptor overexpressed on tumour cells of different origin, with a key role in the development of malignancy. Trastuzumab, the only humanised anti-ErbB2 antibody currently used in breast cancer with success, can engender cardiotoxicity and a high fraction of patients is resistant to Trastuzumab treatment.Methods:A novel human immunoRNase, called anti-ErbB2 human compact antibody-RNase (Erb-hcAb-RNase), made up of the compact anti-ErbB2 antibody Erbicin-human-compact Antibody (Erb-hcAb) and human pancreatic RNase (HP-RNase), has been designed, expressed in mammalian cell cultures and purified. The immunoRNase was then characterised as an enzymatic protein, and tested for its biological actions in vitro and in vivo on ErbB2-positive tumour cells.Results:Erb-hcAb-RNase retains the enzymatic activity of HP-RNase and specifically binds to ErbB2-positive cells with an affinity comparable with that of the parental Erb-hcAb. Moreover, this novel immunoRNase is endowed with an effective and selective antiproliferative action for ErbB2-positive tumour cells both in vitro and in vivo. Its antitumour activity is more potent than that of the parental Erb-hcAb as the novel immunoconjugate has acquired RNase-based cytotoxicity in addition to the inhibitory growth effects, antibody-dependent and complement-dependent cytotoxicity of Erb-hcAb.Conclusion:Erb-hcAb-RNase could be a promising candidate for the immunotherapy of ErbB2-positive tumours.British Journal of Cancer advance online publication, 10 May 2011; doi:10.1038/bjc.2011.146 www.bjcancer.com.

PMID: 21559015